文献速递免疫规划卫生政策与健康促进

爱尔兰三种儿童普遍水痘疫苗接种策略的成本效果经济学评价与增量分析

An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
PubMed 文献 · Vaccine · 2024-04-11

本研究用年龄结构动态传播模型,评估爱尔兰三种儿童普遍水痘疫苗接种策略在80年时间框架下的成本效果。支付方视角下,12月龄一剂策略相比不接种的增量成本效果比为每获得一个质量调整生命年8712欧元;社会视角下三种策略均节省成本,其中12和15月龄两剂短间隔策略占优。

要点

  • 支付方视角下,12月龄一剂策略相比不接种的ICER为每QALY 8712欧元。
  • 支付方视角下,两剂长间隔策略相比一剂策略的ICER为每QALY 45090欧元。
  • 社会视角下三种策略均节省成本,两剂短间隔策略占优,节省最多且健康收益最大。

核心结论

  • 支付方视角下一剂策略因减少住院而极具成本效果,社会视角下两剂策略均节省成本。
  • 结果应结合新疫苗在儿童免疫规划中的可接受性、规划目标和预算影响等其他因素考虑。

研究设计与样本

  • 开发年龄结构动态传播模型模拟水痘带状疱疹病毒传播。
  • 分析三种策略:12月龄一剂、12和15月龄两剂短间隔、12月龄和5岁两剂长间隔。
  • 采用80年时间框架,考虑支付方和社会视角,效果以质量调整生命年表示。
  • 成本以2022年爱尔兰欧元表示,参照每QALY 20000欧元的支付意愿阈值解读成本效果。

主要发现

  • 支付方视角下,一剂策略相比不接种的ICER估计为每QALY 8712欧元。
  • 支付方视角下,两剂长间隔策略相比一剂策略的ICER估计为每QALY 45090欧元。
  • 社会视角下三种策略相比不接种均节省成本,两剂短间隔策略占优,节省成本最多且健康收益最大。
  • 结果在一系列敏感性和情景分析中保持稳定。

关键数值与推荐

  • 支付方视角一剂策略相比不接种:ICER为每QALY 8712欧元。
  • 支付方视角两剂长间隔策略相比一剂策略:ICER为每QALY 45090欧元。
  • 支付意愿阈值为每QALY 20000欧元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cost effectiveness of childhood varicella vaccination is uncertain, as evidenced by variation in national health policies. Within the European Economic Area (EEA), only 10 of 30 countries offer universally funded childhood varicella vaccination. This study estimates the cost effectiveness of universal childhood varicella vaccination for one EEA country (Ireland), highlighting the difference in cost effectiveness between alternative vaccination strategies. METHODS: An age-structured dynamic transmission model, simulating varicella zoster virus transmission, was developed to analyse the impact of three vaccination strategies; one-dose at 12 months old, two-dose at 12 and 15 months old (short-interval), and two-dose at 12 months and five years old (long-interval). The analysis adopted an 80-year time horizon and considered payer and societal perspectives. Clinical effectiveness was based on cases of varicella and subsequently herpes zoster and post-herpetic neuralgia avoided, and outcomes were expressed in quality-adjusted life-years (QALYs). Costs were presented in 2022 Irish Euro and cost effectiveness was interpreted with reference to a willingness-to-pay threshold of €20,000 per QALY gained. RESULTS: From the payer perspective, the incremental cost-effectiveness ratio (ICER) for a one-dose strategy, compared with no vaccination, was estimated at €8,712 per QALY gained. The ICER for the next least expensive strategy, two-dose long-interval, compared with one-dose, was estimated at €45,090 per QALY gained. From a societal perspective, all three strategies were cost-saving compared with no vaccination; the two-dose short-interval strategy dominated, yielding the largest cost savings and health benefits. Results were stable across a range of sensitivity and scenario analyses. CONCLUSION: A one-dose strategy was highly cost effective from the payer perspective, driven by a reduction in hospitalisations. Two-dose strategies were cost saving from the societal perspective. These results should be considered alongside other factors such as acceptability of a new vaccine within the overall childhood immunisation schedule, programme objectives and budget impact.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ahern S, Browne J, Murphy A, et al. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland. Vaccine. 2024. PMID: 38609807. doi:10.1016/j.vaccine.2024.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。